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 Several candidate biomarkers for the early 
detection and assessment of acute kidney 
injury (AKI) are in development, as a 
result of a concerted eff ort to improve the 
timeliness and specifi city of interventions 
in future clinical trials in this patient pop-
ulation. Liver fatty acid-binding protein 
(L-FABP), which is among these promis-
ing new AKI biomarkers, is a member of 
a family of FABPs. In recent years, a 
number of human clinical studies have 
explored the potential utility of urinary 
L-FABP as a biomarker for the early diag-
nosis of AKI. 1 
In this issue, Ferguson and colleagues 2 
provide data that further establish the 
potential clinical utility of urinary L-FABP 
for the diagnostic assessment of AKI in 
hospitalized patients. Th is cross-sectional 
study in 92 patients with AKI and 68 con-
trols (26 healthy volunteers and 42 hospi-
talized patients, including 29 pre-coronary 
catheterization patients and 13 intensive 
care unit patients) establishes that the 
performance of L-FABP in the detection 
and assessment of AKI satisfi es the most 
basic requirements for a useful diagnostic 
test in this syndrome: urinary levels of the 
marker are signifi cantly higher in those 
with AKI than in hospitalized control 
patients without AKI. Th is is refl ected in 
an excellent area under the receiver oper-
ating characteristic curve (ROC-AUC) of 
0.93 (95 % confi dence interval 0.88 – 0.97, 
with a sensitivity of 83 % and a specifi city 
of 90 % at a cutoff  value of 47.1  ng / mg cre-
atinine). 2 Sensitivity (95 % ) and AUC 
(0.96) were improved when normal vol-
unteers were included among the con-
trols, although specifi city decreased to 
84 % with the lower cutoff value of 
26.1  ng / mg creatinine. Regardless, the use 
of healthy volunteers in the assessment of 
a diagnostic test for AKI seems more 
likely to falsely improve test performance 
than to provide clinically useful informa-
tion. Although tending to be lower in 
patients with radiocontrast nephropathy 
as compared with other causes of AKI 
(acute tubular necrosis, sepsis, other neph-
rotoxins), urinary L-FABP levels were not 
signifi cantly diff erent between these etio-
logic AKI subgroups. 
Th e authors also directly compared the 
diagnostic performance of urinary 
L-FABP with that of other emerging 
biomarkers of AKI — neutrophil gelati-
nase-associated lipocalin, kidney injury 
molecule-1,  N -acetyl-  -glucosaminidase, 
and interleukin-18 — and found it compa-
rable to the former 3 markers, and supe-
rior to the latter. These observations 
correlate with earlier studies of human L-
FABP transgenic mice exposed to 
ischemia – reperfusion injury. Urinary 
L-FABP was superior to other biomarkers, 
such as blood urea nitrogen and  N -acetyl-
  -glucosaminidase, for the detection 
of significant histological injuries and 
functional declines by ROC curves. 3 
Finally, Ferguson  et al. 2 performed an 
exploratory age-adjusted logistic regres-
sion analysis of the prognostic value of 
L-FABP to predict renal and nonrenal 
clinical outcomes, and found that urinary 
levels were signifi cantly predictive of the 
need for acute renal replacement therapy 
(RRT) and the composite end point of 
death / RRT, but not of in-hospital mor-
tality. Th us, despite these encouraging 
results, the validation of L-FABP for the 
diagnostic and prognostic assessment of 
AKI is still in its early stages. In particu-
lar, the ability of L-FABP to provide 
early diagnosis of AKI was not tested in 
this study; 2 the study was relatively 
small to establish the value of this 
marker for the diff erential diagnosis of 
AKI etiologies; and the sample size for 
prognostic evaluation was suitable only 
for exploratory analysis. Nonetheless, 
these encouraging results will add impe-
tus to the development of L-FABP as an 
AKI biomarker. 
 Although it is exactly 40 years since its 
discovery by the isolation of two hepatic 
cytoplasmic proteins, our current under-
standing of the mechanism by which 
L-FABP, or FABP1, activates putative anti-
oxidant signals remains surprisingly 
incomplete. 1 Originally known as Z pro-
tein, L-FABP is an intracellular lipid chap-
erone that binds selectively to free 
unsaturated fatty acids and lipid peroxida-
tion products during tissue injury from 
hypoxia. In the kidney, two types of FABPs 
have been found in renal tubule cells: 
L-FABP (FABP1) and heart and muscle 
type (FABP3, or H-FABP). L-FABP is 
solely localized to the cytoplasmic region 
of proximal tubular cells. Increased 
cytosolic L-FABP in proximal tubular epi-
thelial cells may derive not only from 
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endogenous expression but perhaps also 
from circulating L-FABP, which might be 
fi ltered at the glomeruli and  reabsorbed 
by tubular cells. In this scenario, liver 
injury may be a potential contributor to 
the increased urinary levels of L-FABP 
during AKI. This point was nicely 
addressed by Portilla  et al. , 4 who mea-
sured serum and urine L-FABP in patients 
undergoing cardiac surgery. Th ere was a 
signifi cant increase of urinary L-FABP 
levels 4  h aft er the surgery, whereas serum 
L-FABP levels did not begin to increase 
until 12  h postoperatively. Th ese observa-
tions support the concept that the human 
urinary L-FABP level is mostly deter-
mined by proximal tubule injury, rather 
than extrarenal production (from liver 
injury, or systemic infl ammation associ-
ated with cardiopulmonary bypass or sep-
sis). In another study, by Fukuda  et al. , 5 
urinary L-FABP showed a higher sensitiv-
ity and specificity for the diagnosis of 
acute coronary syndrome and was not a 
predictor of AKI in patients undergoing 
coronary angiogram. Th e rise in urinary 
L-FABP levels did not result from con-
trast-induced nephropathy. The study 
highlighted the extrarenal source of uri-
nary L-FABP. Nakamura  et al. 6 demon-
strated that urinary L-FABP levels did not 
correlate with Acute Physiology and 
Chronic Health Evaluation (APACHE) 
scores in septic patients. Urinary L-FABP 
could serve as a biomarker of AKI prima-
rily in septic patients presenting with sep-
tic shock and multiorgan failure, in whom 
the potential for liver involvement could 
present. Th is important concept was not 
addressed by Ferguson  et al. 2 in the cur-
rent study. Th e authors did not include 
information on any of the following: 
serum L-FABP levels with or without AKI; 
APACHE scores; liver function tests; 
or organ injury in patients with septic 
shock, multiorgan failure, and probable 
liver injury. 
 Once in the proximal tubular cells, 
L-FABP may act as a surrogate molecule 
to reduce lipid peroxidative stress during 
reperfusion by binding fatty acid oxida-
tion products and limiting the toxic 
effects of oxidative intermediates on 
cellular membranes. Overexpression of 
L-FABP in mice subjected to renal 
ischemia – reperfusion injury off ers pro-
tection against renal tissue hypoxia. 6 Th e 
urinary levels of L-FABP have been 
reported in several kinds of human clinical 
studies 4,6 – 8 ( Table 1 ) and animal studies 3,9 
of AKI. Taken together, these results 
indicate that L-FABP not only contrib-
utes to the traffi  cking of fatty acids but 
also serves as a diagnostic indicator of 
acute renal diseases. Although Ferguson 
and colleagues 2 have provided further 
evidence that urinary L-FABP can aid in 
the diagnostic and perhaps the prognostic 
evaluation of AKI, several steps in the 
validation process for this urinary biomar-
ker remain to be addressed. 
 What else needs to be done to evaluate 
the utility of this promising AKI bio-
marker? Let ’ s place current knowledge 
of L-FABP biology within a conceptual 
framework of AKI that describes a series 
of stages, antecedents, and outcomes 
( Figure 1 ). 10 In this model, the stages of 
development ( Figure 1 , left  to right) or 
recovery (right to left ) of AKI are high-
lighted. Antecedents (in yellow) of AKI 
 Table 1  |  Clinical studies of L-FABP in AKI 
 Reference  Year  Subjects/Methods  Key results 
 Ferguson  et al. 2  2010  92 patients with established AKI and 68 
control subjects 
 Elevated urinary L-FABP in established AKI of various etiology. 
 Urinary L-FABP as a predictor of adverse renal/nonrenal outcomes. 
 Nakamura  et al. 6  2009  40 patients with septic shock  Urinary L-FABP levels increased in patients with septic shock and may 
correlate with severity of septic shock and response to treatment. 
 No change in serum L-FABP levels. 
 Urinary L-FABP levels not correlated with need for renal replacement 
therapy. 
   
   
 Portilla  et al. 4  2008  40 children undergoing cardiac surgery  Urinary L-FABP levels increased 94- and 45-fold at 4 and 12 hours, 
respectively, following surgery in the 21 patients who developed AKI. 
 Fukuda  et al. 5  2009  27 patients with stable angina or acute 
coronary syndrome undergoing coronary 
angiogram and 12 control volunteers 
 Urinary L-FABP levels were signifi cantly higher in acute coronary 
syndrome than in stable angina. However, none of these patients 
developed contrast-induced nephropathy; L-FABP may be a predictor 
of acute coronary syndrome. 
 Nakamura  et al. 8  2006  66 patients undergoing non-emergency coro-
nary angiography who had a serum creatinine 
level greater than 1.2  mg/dl (>106   mol/l) 
and less than 2.5  mg/dl (  <  221   mol/l) and 30 
healthy volunteers 
 Urinary L-FABP levels were detectable before angiography and pre-
dicted those who developed contrast medium – induced nephropathy. 
 After 14 days, serum creatinine levels returned to normal and L-FABP 
levels remained high. 
 Yamamoto  et al. 7  2007  12 patients with kidney transplants from liv-
ing related donors 
 Urinary L-FABP levels were measured in the fi rst urine produced after 
reperfusion of the transplanted organs. Correlations were found 
between urinary L-FABP level and both peritubular capillary blood fl ow 
and ischemic transplant time. 
 Transition of L-FABP from the cytoplasm of proximal tubular cells to 
the tubular lumen in human L-FABP transgenic mice subjected to renal 
ischemia – reperfusion. 
   
Abbreviations: AKI, acute kidney injury; L-FABP, liver-type fatty acid – binding protein.
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include increased risk in certain patient 
population groups, such as older per-
sons. Outcomes (in purple) include fatal 
or non-fatal complications in other 
organ systems. Kidney damage (in pink) 
is an intermediate stage preceding AKI 
(signaled by glomerular fi ltration rate 
loss and acute elevation of serum creati-
nine). This stage is emphasized here 
because of the potential importance of 
biomarkers in predicting AKI several 
hours to days before the rise in serum 
creatinine, which may allow early AKI 
diagnosis and more rapid implemen-
tation of protective measures (volume 
expansion, vasoactive drug therapy, 
avoidance of nephrotoxins). Although 
some clinical data suggest potential util-
ity of L-FABP for the early diagnosis by 
AKI ( Table 1 ;  Figure 1 ), 4,6,9 the study by 
Ferguson  et al. 2 does not address this 
point. In animal models,  urinary L-FABP 
was observed at 1  h aft er ischemia – reper-
fusion injury. 3 In pediatric patients 
undergoing major cardiac surgery, 
 urinary L-FABP levels were detec table 
4  h postoperatively and were predictive 
of the subsequent development of AKI 
with an ROC-AUC of 0.81. 4 In addition 
to a careful assessment of the ability of 
L-FABP to achieve early diagnosis of 
AKI, future studies should increase the 
depth of the assessment of other 
nonrenal outcomes (length of intensive 
care unit stay, functional status assess-
ment, economic analysis) and renal out-
comes (such as RRT duration, recovery 
of renal function, and / or progression to 
chronic kidney disease). In one cohort 
study of 40 septic patients, 28 survived 
and 12 died. Among the surviving 
patients,  urinary L-FABP levels were 
reduced by treatment. 6 However, the 
non-surviving patients showed higher 
urinary L-FABP levels with smaller 
decreases aft er the treatment as com-
pared with the survivors. Th ese results 
suggested that urinary L-FABP levels 
might be able to refl ect the severity of 
sepsis and the response to treatment. 6 
 In conclusion, the current data from a 
modest number of human subjects sug-
gest a potential role of urinary L-FABP in 
the clinical diagnostic evaluation of AKI. 
Larger multicenter studies that include 
earlier serial urine sampling (to evaluate 
early diagnosis), larger patient cohorts 
(including important subsets such as 
septic patients), and comparison with 
other emerging AKI biomarkers are 
required to continue the development of 
this promising biomarker. 
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 Figure 1  |  L-FABP in a conceptual framework of AKI. (Adapted from ref. 10.) AKI, acute kidney injury; GFR, glomerular filtration rate; L-FABP, liver-type fatty 
acid–binding protein.  
